Results of Operations and Financial Condition. On August 12, 2026, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2026 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this

Chief Medical Officer — Adrian Quartel, M.D., FFPM: Dr. Adrian Quartel was appointed as the Chief Medical Officer, bringing extensive experience in pharmaceutical industry.

Results of Operations and Financial Condition. On May 13, 2026, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company also reported cash and cash equivalents of $107.3 million as of April 30, 2026. This estimate is preliminary…

Entry into a Material Definitive Agreement. On April 20, 2026, Spruce Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc., as representatives of the several underwriters listed therein (collectively, the “Underwriters”), to issue and sell 1,150,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a price to…

Termination of a Material Definitive Agreement. On March 16, 2026, Spruce Biosciences, Inc. (the “Company”) entered into a Termination Agreement (the “Termination Agreement”) with Kaken Pharmaceutical Co., Ltd. (“Kaken”) to terminate by mutual agreement that certain Collaboration and License Agreement, dated as of January 5, 2023, by and between the Company and Kaken (the “Collaboration Agreement”). The Collaboration Agreement will terminate effective as of March 31, 2026 (the “Termination Da…

Chief Commercial Officer — Corwin Dale Hooks: The company appointed Corwin Dale Hooks as the Chief Commercial Officer.

Results of Operations and Financial Condition. On March 9, 2026, the Company issued a press release announcing its financial results for the full year ended December 31, 2025 and providing corporate updates (the “Press Release”). The full text of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this

Entry into a Material Definitive Agreement. On March 9, 2026, Spruce Biosciences, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Jefferies as its sales agent and/or principal, shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering amount not exceeding the Maximum Pr…

Termination of a Material Definitive Agreement. The information set forth above in

Other Events. The Presentation included final results from the Company’s new analyses of its existing data from Observational Study 902 and Interventional Studies 250-201, 250-202, and 250-401 for the treatment of MPS IIIB using the validated Vineland Adaptive Behavior Scales, Second Edition (“VABS-II”) scale. These new analyses showed that TA-ERT treatment was associated with a stabilization in receptive and expressive communication, as well as both fine and gross motor skills, compared to a…

Results of Operations and Financial Condition. On January 8, 2026, the Company announced that its preliminary unaudited cash and cash equivalents as of December 31, 2025 were approximately $48.9 million. The Company has not yet completed its quarter-end and year-end financial close process for the quarter and year ended December 31, 2025. This estimate of the Company’s cash and cash equivalents as of December 31, 2025 is preliminary, has not been audited and is subject to change upon completi…

Entry into a Material Definitive Agreement. Loan Agreement On January 7, 2026 (the “Closing Date”), Spruce Biosciences, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan and Security Agreement”) and a Supplement to the Loan and Security Agreement (together with the Loan and Security Agreement, the “Loan Agreement”), with Avenue Capital Management II, L.P., as administrative agent and collateral agent (the “Agent”) and Avenue Venture Opportunities Fund II, L.P., as len…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth under

The securities described above will be offered and sold in reliance upon an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The Loans, Warrant and any shares of Common Stock issuable thereunder have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC, or an applicable exemption from the registration requirements.

Director — Keli Walbert: Appointment of Keli Walbert as a Director and to the Compensation Committee.

Director — Tiba Aynechi, Ph.D.: Dr. Tiba Aynechi resigned from the board of directors and as Chair of the Compensation Committee.

Results of Operations and Financial Condition. On November 10, 2025, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2025 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this

Director — Bali Muralidhar, Ph.D.: Dr. Bali Muralidhar resigned from the board of directors and compensation committee.

Unregistered Sales of Equity Securities. The disclosure regarding the securities to be sold and issued under the Purchase Agreement as set forth under

Entry into a Material Definitive Agreement. Private Placement On October 7, 2025, Spruce Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers (i) 502,181 shares of the Company’s common stock (“Common Stock”) and (ii) pre-funded warrants to purchase up to 233,144 shares of Common Stock (the “Pre-Funded Warrants”)…

Results of Operations and Financial Condition. On August 14, 2025, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this

Material Modification to Rights of Security Holders. To the extent applicable, the information in

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. To the extent applicable, the information in

by reference. The Purchaser is an “accredited investor” and the offer and sale of the share of Series A Preferred was exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.

Entry into a Material Definitive Agreement. On May 28, 2025, Spruce Biosciences, Inc., a Delaware corporation (the “Company”), entered into a Purchase Agreement (the “Purchase Agreement”) with Michael Grey, the Executive Chair of the Company’s Board of Directors (“Purchaser”), pursuant to which the Company issued and sold one share of the Company’s newly designated Series A Preferred Stock, par value $0.0001 per share (the “Series A Preferred”), to the Purchaser for a purchase price of $100.0…